Oncolytics Biotech, Inc. (NASDAQ:ONCYF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Friday.

According to Zacks, “Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway, one of the most common family of genetic defects leading to cancer. “

Shares of Oncolytics Biotech (ONCYF) opened at 0.39 on Friday. The stock’s market capitalization is $54.38 million. The firm has a 50-day moving average of $0.40 and a 200 day moving average of $0.44. Oncolytics Biotech has a 52-week low of $0.14 and a 52-week high of $0.85.

ILLEGAL ACTIVITY NOTICE: “Oncolytics Biotech, Inc. (NASDAQ:ONCYF) Rating Lowered to Sell at Zacks Investment Research” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/oncolytics-biotech-inc-nasdaqoncyf-rating-lowered-to-sell-at-zacks-investment-research/1471584.html.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company’s clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials.

Get a free copy of the Zacks research report on Oncolytics Biotech (ONCYF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oncolytics Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.